Evidence map›Paper›PMID 32110403›Full record

ReviewSAGE open medicine2020

Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper).

Rafiye Ciftciler, Ali Erdinc Ciftciler, Umit Yavuz Malkan, Ibrahim C Haznedaroglu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in SAGE open medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Antineoplastic Effects of Ankaferd Hemostat.BioMed research international · 2022
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Rafiye CiftcilerDepartment of Hematology, Faculty of Medicine, Hacettepe University Medical School, Ankara, Turkey.ORCID https://orcid.org/0000-0001-5687-8531
Ali Erdinc CiftcilerDepartment of General Surgery, Kizilcahamam State Hospital, Ankara, Turkey.
Umit Yavuz MalkanDepartment of Hematology, Diskapi Education and Research Hospital, Ankara, Turkey.
Ibrahim C HaznedarogluDepartment of Hematology, Faculty of Medicine, Hacettepe University Medical School, Ankara, Turkey.
Hacettepe University · TRDışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi · TRSivas State Hospital · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ankaferd hemostat (Ankaferd blood stopper [ABS], Istanbul, Turkey) is a hemostatic agent affecting red blood cell-fibrinogen interactions. ABS has been traditionally used in Anatolia as a hemostatic agent for centuries. ABS contains a standardized combination of the plants namely

Indexed as

Ankaferd hemostatcancerclinical hemorrhagesinfectionswound healing

Identifiers

PMID32110403
PMCPMC7026817
OpenAlexW3006110350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.